Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis

After the results of first multicenter, prospective randomized clinical trial (RCT) evaluating long-term efficacy oral beta-blockers in patients with preserved left ventricular ejection fraction (LVEF) after ST elevation myocardial infarction (STEMI), we decided to conduct an updated systematic review and meta-analysis evaluate beta-blocker use LVEF who underwent percutaneous coronary intervention (PCI) for STEMI. A time-limited search from January 1, 1999, April 16, 2020, on PubMed EMBASE was conducted observational studies trials STEMI treated PCI. The comparative outcomes between non–beta-blockers were assessed by pooling weighted odds ratio (OR) 95% confidence interval (CI) using random-effects model. interest all-cause mortality major adverse cardiac event (MACE). Twelve (11 1 RCT) comprising 32,108 (19,740 therapy 12,368 without therapy) included. Of which, 75% percent male (mean age 64 years: 63.87 ± 3.01 years 64.76 3.02 non–beta-blocker therapy; P = 0.129) a follow-up up 4.7 years. Unadjusted [OR 0.58 (95% CI: 0.42–0.79)] adjusted 0.64 0.48–0.87)] significantly lower group. However, unadjusted MACE 0.87 0.70–1.08)] not reduced these patients. Patients PCI have significant reduction risk mortality, effect rates. only RCT included showed neutral effect, so ongoing RCTs are anticipated. Considering that high-quality data suggest one should be cautious interpreting conclusion.